MeiraGTx Holdings plc
NASDAQ:MGTX · NASDAQ Global Select
+$0.53 today
Vol 2.22M · Avg 0.84M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
1971.4%
avg 156.4%
ROIC
-70.9%
avg -107.0%
ROA
-46.7%
avg -51.8%
Analysis
ROE is currently the strongest return metric at 1971.4% versus its period average of 156.4%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Alexandria Forbes | Chief Executive Officer, President & Director | $2.51M | — | 61 | $1.39M | 1.50% |
Richard Brian Giroux | Chief Operating Officer & Chief Financial Officer | $2.33M | — | 52 | $964,530.00 | 1.04% |
Stuart Naylor | Chief Scientific Officer of Ophthalmology | $1.10M | — | 63 | $668,505.00 | 0.72% |
Robert K. Zeldin | Chief Medical Officer | $1.06M | — | 63 | $175,840.00 | 0.19% |
David Rubinstein | Senior Vice President of Business Development | — | — | — | — | — |
Michel Michaelides | Head of Clinical Ophthalmology | — | — | — | — | — |
Tassos Georgiadis | Senior Vice President of Discovery & Preclinical Development | — | — | — | — | — |
Robert J. Wollin | General Counsel & Secretary | — | — | 50 | $175,840.00 | 0.19% |
Tim Randall | Senior Vice President of Risk & Internal Controls | — | — | — | — | — |
Christine Elise Sheehy | Senior Vice President of Global Integration | — | — | 58 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
8
$3.05M
Net Sentiment
$3.05M
Net selling
Most Active
Forbes Alexandria
4 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 8 sells worth $3.05M over the last 12 months. That adds up to net selling of $3.05M. Forbes Alexandria was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +43.0% (10yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +43.0% (10yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Erasca, Inc.
NASDAQ:ERAS
$4.33B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.47B
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.43B
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$1.40B
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
$1.38B
Absci Corporation
NASDAQ:ABSI
$1.13B
Replimune Group, Inc.
NASDAQ:REPL
$838.94M
Astria Therapeutics, Inc.
ATXS
$718.13M
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$577.80M
Arvinas, Inc.
NASDAQ:ARVN
$487.14M
Who manages MGTX?
MeiraGTx Holdings plc (MGTX) lists 10 active executives. The top listed executive is Alexandria Forbes, Chief Executive Officer, President & Director.
Are MGTX insiders buying or selling?
Recent insider activity shows net selling of $25.41M.
Explore More
Continue the stock analysis
Jump to another research area for this company.